Managing acquired resistance in EGFR-mutated non–small cell lung cancer

Clinical Advances in Hematology and Oncology

Volumn 13, Issue 8, 2015, Pages 528-532

  Forde, Patrick M ^a   Ettinger, David S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

EGFR mutations; Epidermal growth factor receptors; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ASP 8273; AZD 6094; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; HM 61713; MERELETINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PLATINUM; ROCILETINIB; SELUMETINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER GROWTH; DISEASE COURSE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HUMAN; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; POINT MUTATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CETUXIMAB; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG; LUNG NEOPLASMS; POINT MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84939552778     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012;18(22):6169-6177.
2. Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH. EGFR and KRAS mutations in patients with adenocarcinoma of the lung. Korean J Intern Med. 2009;24(1):48-54.
3. Wu SG, Gow CH, Yu CJ, et al. Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. Eur Respir J. 2008;32(4):924-930.
4. Gilotrif [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf.
5. Tarceva [package insert]. South San Francisco, CA: Genentech; 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf.
6. Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-222.
7. Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327-3334.
8. Rosell R, Carcereny E, Gervais R, et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-246.
9. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735-742.
10. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011;17(5):1169-1180.
11. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
12. Yano S, Yamada T, Takeuchi S, et al. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol. 2011;6(12):2011-2017.
13. Uramoto H, Shimokawa H, Hanagiri T, Kuwano M, Ono M. Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma. Lung Cancer. 2011;73(3):361-365.
14. Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922-933.
15. Mok TSK, Nakagawa W, Kim S, et al. Gefitinib/chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after progression on first-line gefitinib: the phase III, randomised IMPRESS study [ESMO abstract LBA2]. Ann Oncol. 2014;25(suppl 4).
16. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012;13(5):528-538.
17. Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013;31(27):3335-3341.
18. Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014;4(9):1036-1045.
19. Cross DAE, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046-1061.
20. Janne PA, Ramalingam SS, Yang JC-H, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant nonsmall cell lung cancer (NSCLC) [ASCO abstract 8009]. J Clin Oncol. 2014;32(5)(suppl).
21. Walter AO, Sjin RTT, Haringsma HJ, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013;3(12):1404-1415.
22. Sequist LV, Soria J-C, Gadgeel SM, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M) [ASCO abstract 8010]. J Clin Oncol. 2014;32(5)(suppl).
23. Soria J-C Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer [EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics abstract LBA10]. Eur J Ca. 2014;50(6)(suppl).
24. Kim D-W, Lee DH, Kang JH, et al. Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced nonsmall cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs) [ASCO abstract 8011]. J Clin Oncol. 2014;32(5)(suppl).
25. Marukami H Antitumour activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumours harbouring EGFR activating mutations and T790M resistance mutation. [EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics abstract LBA9]. Eur J Ca. 2014;50(6)(suppl).
26. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-2247.
27. Reckamp KL, Frankel PH, Mack PC, et al. Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California Cancer Consortium phase II trial (NCI 9303) [ASCO abstract 8014]. J Clin Oncol. 2014;32(5)(suppl).
28. Wu Y-L, Yang JC-H, Kim D-W, et al. Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase lb/ll study [ASCO abstract 8017]. J Clin Oncol. 2014;32(5)(suppl).
29. Janne PA, Shaw AT, Giaccone G, et al. Phase I trial of irreversible pan-ERBB inhibitor dacomitinib in combination with ALK/MET inhibitor crizotinib in previously treated advanced non-small cell lung cancer [ESMO abstract 1290P]. Ann Oncol. 2012;23(suppl 9).
30. Lara P, Longmate J, Mack PC, et al. Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: a California Cancer Consortium phase II trial (NCI 8698) [ASCO abstract 8015]. J Clin Oncol. 2014;32(5)(suppl).